| __timestamp | AbbVie Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 3297000000 | 1513000 |
| Thursday, January 1, 2015 | 4285000000 | 12573000 |
| Friday, January 1, 2016 | 4366000000 | 42238000 |
| Sunday, January 1, 2017 | 4982000000 | 69800000 |
| Monday, January 1, 2018 | 10329000000 | 113773000 |
| Tuesday, January 1, 2019 | 6407000000 | 179362000 |
| Wednesday, January 1, 2020 | 6557000000 | 266946000 |
| Friday, January 1, 2021 | 7084000000 | 438633000 |
| Saturday, January 1, 2022 | 6510000000 | 461645000 |
| Sunday, January 1, 2023 | 8453000000 | 387332000 |
| Monday, January 1, 2024 | 12791000000 | 320653000 |
Data in motion
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, AbbVie Inc. and CRISPR Therapeutics AG have demonstrated contrasting approaches to R&D investment. AbbVie, a pharmaceutical powerhouse, has consistently allocated substantial resources, with R&D expenses peaking at approximately $10 billion in 2018. This represents a staggering 200% increase from 2014. In contrast, CRISPR Therapeutics, a pioneer in gene editing, has shown a more modest yet significant growth in R&D spending, increasing nearly 300 times from 2014 to 2023. By 2023, CRISPR's R&D budget reached nearly $400 million, highlighting its growing influence in the biotech sector. This comparison underscores the diverse strategies employed by industry leaders to drive innovation and maintain competitive edges in a rapidly advancing field.
Comparing Innovation Spending: Novo Nordisk A/S and AbbVie Inc.
AbbVie Inc. or Gilead Sciences, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: AbbVie Inc. and Veracyte, Inc.
AbbVie Inc. vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: United Therapeutics Corporation vs CRISPR Therapeutics AG
Analyzing R&D Budgets: Insmed Incorporated vs CRISPR Therapeutics AG
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs CRISPR Therapeutics AG
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Mesoblast Limited
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.